BioChem Pharma received FDA approval of Epivir-HBV as first oral treatment for chronic hepatitis B patients.BioChem Pharma, Inc., Laval, Quebec, Canada, announced the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has approved Epivir-HBV (lamivudine) tablets and oral solution as the first oral, antiviral medication for the treatment of adults with chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis B associated with evidence of hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic viral replication and active liver inflammation. The company says the goal of hepatitis B therapy is reducing the progressive liver inflammation that occurs when the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. attacks hepatitis B-infected liver cells. Epivir-HBV acts directly to interfere with viral replication, leading to reduced inflammatory response to HBV HBV hepatitis B virus. HBV abbr. hepatitis B virus infection in the liver. The World Health Organization estimates HBV is the ninth most common cause of death worldwide. Approximately 350 million people, 5% of the world's population, have chronic infection with HBV and about one-third of these individuals are at risk for serious progressive liver disease. The CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation estimates there are approximately 1 million Americans with HBV and only a small number have been treated. BioChem says lamivudine has been filed for approval in more than 30 countries and has already been approved in the Philippines, New Zealand, Pakistan and Canada. Under terms of a license agreement, BioChem will receive royalties from Glaxo Wellcome on sales of lamivudine. Glaxo Wellcome has the right to develop, manufacture and sell lamivudine worldwide, subject to special arrangements for Canada, where BioChem Pharma and Glaxo Wellcome have formed a commercial partnership. Contact: Michele Roy - (450) 978-7771 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion